Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02732184 · ClinicalTrials.gov registry record · Phase 2
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
A Phase 2 study, sponsored by Aeglea Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT02732184: Completed Phase 2 study, sponsored by Aeglea Biotherapeutics.
NCT02732184 is a Phase 2 study that has completed, run by Aeglea Biotherapeutics. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02732184, a Phase 2 study, has completed, sponsored by Aeglea Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is the first study of the safety of increasing dose levels of AEB1102 in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and the antitumor effects of AEB1102.
Primary Outcome
The dose level at which no more than 1/6 patients experiences dose-limiting toxicity
Interventions
- DRUG Co-ArgI-PEG modified human arginase I
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
What the finished NCT02732184 record still lists
NCT02732184 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 1 intervention - of which Co-ArgI-PEG modified human arginase I is the first listed.
NCT02732184 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02732184 about?
NCT02732184 is a clinical study titled "A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS". This is the first study of the safety of increasing dose levels of AEB1102 in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and the antitumor eff...
What is the current status of trial NCT02732184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2016-08. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02732184?
The interventions under investigation include: Co-ArgI-PEG modified human arginase I (DRUG).
Who is sponsoring clinical trial NCT02732184?
This trial is sponsored by Aeglea Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02732184's enrollment target sits among peer trials
29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia